FCF Payout Ratio: N/A
The FCF payout ratio is N/A.
EW FCF Payout Ratio Metrics
FCF PAYOUT RATIO
N/A
Payout Ratio Comparison
FCF Payout Ratio TTM
N/A
Earnings Payout Ratio
N/A
Dividend Yield
N/A
FCF Yield
2.07%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $1.33B | $0 | 0.0% |
| 2024 | $289.90M | $0 | 0.0% |
| 2023 | $629.50M | $0 | 0.0% |
| 2022 | $953.40M | $0 | 0.0% |
| 2021 | $1.40B | $0 | 0.0% |
| 2020 | $647.00M | $0 | 0.0% |
| 2019 | $901.00M | $0 | 0.0% |
| 2018 | $685.10M | $0 | 0.0% |
| 2017 | $825.20M | $0 | 0.0% |
| 2016 | $487.00M | $0 | 0.0% |
| 2015 | $443.20M | $0 | 0.0% |
| 2014 | $928.60M | $0 | 0.0% |
| 2013 | $362.60M | $0 | 0.0% |
| 2012 | $246.10M | $0 | 0.0% |
| 2011 | $223.90M | $0 | 0.0% |
| 2010 | $188.40M | $0 | 0.0% |
| 2009 | $101.30M | $0 | 0.0% |
| 2008 | $75.20M | $0 | 0.0% |
| 2007 | $147.70M | $0 | 0.0% |
| 2006 | $171.40M | $0 | 0.0% |
| 2005 | $88.30M | $0 | 0.0% |
| 2004 | $138.10M | $0 | 0.0% |
| 2003 | $84.40M | $0 | 0.0% |
| 2002 | $79.90M | $0 | 0.0% |
| 2001 | $63.00M | $0 | 0.0% |
| 2000 | $91.00M | $0 | 0.0% |
| 1999 | $134.00M | $0 | 0.0% |
Formula: FCF Payout Ratio TTM = trailing 4Q dividends paid / trailing 4Q free cash flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures trailing dividends paid as a percentage of trailing free cash flow. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian